Our full menu of genetic testing provides the highest quality molecular assays available. Utilization of next-generation sequencing (NGS) in our profiles enables better technical resolution of complex somatic variants, providing precision insights to facilitate diagnosis, prognosis, and therapeutic management. Our comprehensive, 47-gene MayoComplete panel and our focused acute myeloid leukemia (AML) subpanels give clinicians the flexibility to order the right tests for their patients.
Next-generation sequencing Test menu
Better testing, better outcomes
Our next-generation sequencing assays not only provide individualized answers for personalized care, but offer numerous advantages, including:
Full access to Mayo Clinic expertise
The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.
Fill out the form below and one of our specialists will be in touch.